Review Opinion of the Compensation and Assessment Committee on the Company's 2025 Restricted Stock Incentive Plan
Beijing Ruimait Medical Technology Co., Ltd. (hereinafter referred to as "the Company") Compensation and Assessment Committee of the Board of Directors, based on the "Company Law of the People's Republic of China," "Securities Law of the People's Republic of China," "Administrative Measures for Equity Incentives of Listed Companies" (hereinafter referred to as "the Administrative Measures"), "Listing Rules of the Shenzhen Stock Exchange for Growth Enterprise Market" (hereinafter referred to as "the Listing Rules"), and other relevant laws, regulations, normative documents, and the Articles of Association of Beijing Ruimait Medical Technology Co., Ltd. (hereinafter referred to as "the Articles of Association"), conducted a review of the adjustments to the grant price of the 2025 Restricted Stock Incentive Plan, the cancellation of unvested restricted stocks that have been granted, and the eligibility of the first vesting period. The review opinions are as follows: